Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR421869 in Usher Syndrome Type 1B
NCT01505062Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2012
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of SAR421869 in Usher syndrome type 1B (USH1B), sponsored by Sanofi. Started Mar 2012; status: terminated.
02
Drugs
SAR421869
03
Conditions
Usher syndrome type 1B (USH1B)
Beyond the preview
Go deeper on NCT01505062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505062.